MILLENNIUM MANAGEMENT LLC - AUTOLUS THERAPEUTICS PLC ownership

AUTOLUS THERAPEUTICS PLC's ticker is AUTL and the CUSIP is 05280R100. A total of 67 filers reported holding AUTOLUS THERAPEUTICS PLC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
MILLENNIUM MANAGEMENT LLC ownership history of AUTOLUS THERAPEUTICS PLC
ValueSharesWeighting
Q1 2023$663
+177.4%
360,145
+186.6%
0.00%
Q4 2022$239
-99.9%
125,650
+59.0%
0.00%
Q3 2022$169,000
-74.9%
79,010
-66.8%
0.00%
Q2 2022$673,000
-3.7%
237,659
+41.8%
0.00%
Q1 2022$699,000
-56.6%
167,566
-46.0%
0.00%
-100.0%
Q4 2021$1,611,000
-44.5%
310,324
-30.0%
0.00%
-50.0%
Q3 2021$2,904,000
-39.7%
443,431
-38.9%
0.00%
-33.3%
Q2 2021$4,815,000
+267.8%
725,172
+217.3%
0.00%
+200.0%
Q1 2021$1,309,000
+374.3%
228,509
+640.2%
0.00%
Q4 2020$276,000
-84.0%
30,873
-79.2%
0.00%
-100.0%
Q3 2020$1,726,000
-85.2%
148,320
-79.6%
0.00%
-87.5%
Q2 2020$11,651,000
+148.4%
726,841
-7.2%
0.02%
+45.5%
Q1 2020$4,691,000
-47.5%
783,164
+15.8%
0.01%0.0%
Q4 2019$8,930,000
-48.5%
676,481
-51.5%
0.01%
-59.3%
Q3 2019$17,340,000
+40.3%
1,396,142
+81.8%
0.03%
+42.1%
Q2 2019$12,362,000
-12.8%
767,836
+70.5%
0.02%
-9.5%
Q1 2019$14,173,000
+3590.9%
450,362
+3749.2%
0.02%
+2000.0%
Q4 2018$384,000
-64.6%
11,700
-67.5%
0.00%0.0%
Q3 2018$1,084,000
-72.3%
35,958
-75.4%
0.00%
-80.0%
Q2 2018$3,910,000145,9450.01%
Other shareholders
AUTOLUS THERAPEUTICS PLC shareholders Q1 2022
NameSharesValueWeighting ↓
Syncona Portfolio Ltd 21,346,829$49,738,11274.10%
TFG Asset Management GP Ltd 12,000,000$27,960,0005.10%
Paradigm Biocapital Advisors LP 14,406,782$33,567,8022.28%
Lynx1 Capital Management LP 1,363,025$3,175,8482.10%
Deep Track Capital, LP 15,000,000$34,950,0001.35%
Affinity Asset Advisors, LLC 1,992,466$4,642,4461.31%
DAFNA Capital Management LLC 928,253$2,162,8290.67%
Frazier Life Sciences Management, L.P. 3,746,857$8,730,1770.58%
ARMISTICE CAPITAL, LLC 6,900,000$16,077,0000.25%
Blackstone Inc. 20,485,611$47,731,4740.20%
View complete list of AUTOLUS THERAPEUTICS PLC shareholders